The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | Evaluating first-line olomorasib and chemo-IO in KRAS G12C NSCLC
Marcelo Negrao, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses results from the LOXO-RAS-20001 (NCT04956640) and SUNRAY-01 (NCT06119581) trials, evaluating olomorasib, a second-generation KRAS G12C inhibitor, in combination with chemoimmunotherapy in first-line advanced non-small cell lung cancer (NSCLC). The regimen showed an encouraging overall response rate regardless of PD-L1 expression. Safety was manageable, with most adverse events controlled through dose modifications. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
